CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
SAGE-547 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02614547
NCT02614547Phase 2Completed
CompareCT.gov

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating The Efficacy, Safety, And Pharmacokinetics Of SAGE-547 Injection In The Treatment Of Adult Female Subjects With Severe Postpartum Depression

Supernus Pharmaceuticals, Inc.·interventional·Posted Nov 25, 2015·Updated Sep 15, 2025

In Brief

A Phase 2 clinical trial evaluating SAGE-547 and Placebo for Severe Postpartum Depression. Completed, enrolled 21 participants across 4 sites.

Detailed Summary

This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy, safety, and pharmacokinetics of SAGE-547 Injection in adult female participants diagnosed with severe postpartum depression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSevere Postpartum Depression
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 25, 2015
Enrollment StartDec 15, 2015
Primary CompletionJun 22, 2016
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 10.6 years ago

Interventions

SAGE-547drug

Administered as intravenous infusion.

Placebodrug

Administered as intravenous infusion.